Cargando...
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
Biliary tract carcinomas (BTC) are malignant tumors with limited therapeutic options. Clinical experiences with anti-EGFR therapies have produced unsatisfactory results. The strategies of combined inhibition of EGFR and MEK1/2 could be a promising therapeutic option in BTC treatment. Preclinical act...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5239557/ https://ncbi.nlm.nih.gov/pubmed/27429047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10587 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|